Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 6
1995 43
1996 97
1997 148
1998 198
1999 253
2000 291
2001 318
2002 354
2003 352
2004 379
2005 361
2006 349
2007 393
2008 343
2009 352
2010 336
2011 338
2012 345
2013 303
2014 266
2015 266
2016 236
2017 166
2018 159
2019 78
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

6,113 results
Results by year
Filters applied: . Clear all
Page 1
The Structural Biology of Bcl-x(L).
Lee EF and Fairlie WD. Int J Mol Sci 2019 - Review. PMID 31067648 Free PMC article.
Interactions between the pro-survival and pro-apoptotic members of the Bcl-2 family of proteins dictate whether a cell lives or dies. Much of our knowledge of the molecular details of these interactions has come from biochemical and structural studies on the pro-survival protein Bcl-x(L). ...
Interactions between the pro-survival and pro-apoptotic members of the Bcl-2 family of proteins dictate whether a cell lives o …
A selective BCL-X(L) PROTAC degrader achieves safe and potent antitumor activity.
Khan S, et al. Nat Med 2019. PMID 31792461 Free PMC article.
B-cell lymphoma extra large (BCL-X(L)) is a well-validated cancer target. However, the on-target and dose-limiting thrombocytopenia limits the use of BCL-X(L) inhibitors, such as ABT263, as safe and effective anticancer agents. To reduce the toxicity of ABT263, we converted it into DT2216, a BCL-X(L) proteolysis-targeting chimera (PROTAC), that targets BCL-X(L) to the Von Hippel-Lindau (VHL) E3 ligase for degradation. ...
B-cell lymphoma extra large (BCL-X(L)) is a well-validated cancer target. However, the on-target and dose-limiting thrombocyto …
Bcl-x(L) deamidation is regulated by multiple ion transporters and is intramolecularly catalyzed.
Dho SH, et al. Biochim Biophys Acta Mol Cell Res 2018. PMID 29694915 Free article.
The rate of nonenzymatic deamidation of two asparagines in the anti-apoptotic protein Bcl-x(L) is accelerated by this increase in pH. ...The conservation of such histidines implies that human Bcl-x(L) is in essence "designed" to be deamidated, which provides further evidence that deamidation serves as a bona fide regulatory post-translational modification of Bcl-x(L)....
The rate of nonenzymatic deamidation of two asparagines in the anti-apoptotic protein Bcl-x(L) is accelerated by this i …
New agents that target senescent cells: the flavone, fisetin, and the BCL-X(L) inhibitors, A1331852 and A1155463.
Zhu Y, et al. Aging (Albany NY) 2017. PMID 28273655 Free PMC article.
Here we report that fisetin, a naturally-occurring flavone with low toxicity, and A1331852 and A1155463, selective BCL-X(L) inhibitors that may have less hematological toxicity than the less specific BCL-2 family inhibitor navitoclax, are senolytic. ...
Here we report that fisetin, a naturally-occurring flavone with low toxicity, and A1331852 and A1155463, selective BCL-X(L) in …
Structural basis for the interaction between DJ-1 and Bcl-X(L).
Lee MK, et al. Biochem Biophys Res Commun 2018. PMID 29175327
DJ-1 is a multifunctional protein associated with Parkinson's disease (PD) and tumorigenesis. In response to ultraviolet B (UVB) irradiation, DJ-1 is translocated into the mitochondria, and its interaction with the mitochondrial protein Bcl-X(L) protects cells against death. ...In addition, our results showed that the C-terminal α8-helix peptide (Cpep) of DJ-1 binds to the pro-apoptotic BH3 peptide-binding hydrophobic groove in Bcl-X(L) and, thus, acts as a Bcl-X(L)-binding motif. ...
DJ-1 is a multifunctional protein associated with Parkinson's disease (PD) and tumorigenesis. In response to ultraviolet B (UVB) irra …
Mcl-1 and Bcl-x(L) sequestration of Bak confers differential resistance to BH3-only proteins.
Hockings C, et al. Cell Death Differ 2018. PMID 29459767 Free PMC article.
The prosurvival Bcl-2 family proteins Mcl-1 and Bcl-x(L) inhibit apoptosis by sequestering BH3-only proteins such as Bid and Bim (MODE 1) or the effector proteins Bak and Bax (MODE 2). ...In a Bim and Bak mixture, Bcl-x(L) and Mcl-1 each sequestered not only Bim but also Bak as it became activated by Bim. In contrast, in a Bid and Bak mixture, Bcl-x(L) preferentially sequestered Bid while Mcl-1 preferentially sequestered Bak. ...
The prosurvival Bcl-2 family proteins Mcl-1 and Bcl-x(L) inhibit apoptosis by sequestering BH3-only proteins
BCL-X expression in oral cancer: Comparison between oral squamous cell carcinoma and verrucous carcinoma.
Shukla P, et al. Indian J Dent Res 2018. PMID 29652014 Free article.
The relationship between this Bcl-X protein and carcinomatous behavior toward it is not studied extensively, which we attempted to evaluate using immunohistochemical analysis in selected carcinomas of the head and neck region. METHOD: We studied Bcl-X protein expression in sections of thirty OSCC and ten VC samples and correlated this with tumor differentiation. ...
The relationship between this Bcl-X protein and carcinomatous behavior toward it is not studied extensively, which we a …
BCL-x(L)-selective BH3 mimetic sensitizes rhabdomyosarcoma cells to chemotherapeutics by activation of the mitochondrial pathway of apoptosis.
Faqar-Uz-Zaman SF, et al. Cancer Lett 2018. PMID 28947136
BH3 mimetics are a promising new class of anticancer agents that inhibit antiapoptotic BCL-2 proteins. Here, we report that BH3 mimetics selectively targeting BCL-x(L), BCL-2 or MCL-1 (i.e. ...Similarly, genetic knockdown of BCL-x(L) primes RMS cells to VCR- or ETO-induced cell death, highlighting the importance of BCL-x(L) in mediating chemotherapy resistance in RMS. ...
BH3 mimetics are a promising new class of anticancer agents that inhibit antiapoptotic BCL-2 proteins. Here, we report that BH …
Discoveries and controversies in BCL-2 protein-mediated apoptosis.
Zheng JH, et al. FEBS J 2016 - Review. PMID 26411300 Free article.
How soluble BCL-2 proteins interact is well understood. Anti-apoptotic proteins, such as BCL-2 and BCL-xL, and the pro-apoptotic effectors of MOMP, including BAK and BAX, interact with pro-apoptotic BCL-2 homology 3 (BH3)-only proteins similarly. ...The anti-apoptotic BCL-2 proteins also inhibit the activated effectors. p53 is a direct BAX activator inhibited by BCL-xL, defining a prototype non-canonical modulator of BCL-2 proteins-mediated MOMP. ...
How soluble BCL-2 proteins interact is well understood. Anti-apoptotic proteins, such as BCL-2 and BCL-xL …
Bcl-x(L)/Bak interaction and regulation by miRNA let-7b in the intrinsic apoptotic pathway of stored platelets.
Yan Y, et al. Platelets 2019. PMID 29125379
We detected a significant decrease in antiapoptotic Bcl-x(L) and increase in proapoptotic Bak expression on the third day of storage and as a result the ratio of Bak:Bcl-x(L) also decreased. ...We also determined that let-7b was upregulated during platelet storage, and let-7b transfection influenced Bcl-x(L) and Bak protein, but not mRNA, expression. ...
We detected a significant decrease in antiapoptotic Bcl-x(L) and increase in proapoptotic Bak expression on the third day of s …
6,113 results
Jump to page
Feedback